Immunogenic compositions for Streptococcus agalactiae

US8945589B2 · kind B2 · utility

Assignee

• Novartis Vaccines and Diagnostics, Inc. · US

Inventors

• John Telford · Colle di Val d'Elsa, IT
• Guido Grandi · Segrate, IT
• Immaculada Margarit Y Ros · Siena, IT
• Domenico Maione · Siena, IT

Key dates

• Filing date: Sep 15, 2004
• Grant date: Feb 3, 2015
• Expiry date: Oct 2, 2029

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/825
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.